Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Oct 21;16(10):e72080.
doi: 10.7759/cureus.72080. eCollection 2024 Oct.

Recent Advances and Therapeutic Benefits of Glucagon-Like Peptide-1 (GLP-1) Agonists in the Management of Type 2 Diabetes and Associated Metabolic Disorders

John O Olukorode  1 , Dolapo A Orimoloye  2 , Nwachukwu O Nwachukwu  3 , Chidera N Onwuzo  4   5   6 , Praise O Oloyede  1 , Temiloluwa Fayemi  1 , Oluwatobi S Odunaike  1 , Petra S Ayobami-Ojo  7 , Nwachi Divine  1 , Demilade J Alo  1 , Chukwurah U Alex  8
Affiliations
Review

Recent Advances and Therapeutic Benefits of Glucagon-Like Peptide-1 (GLP-1) Agonists in the Management of Type 2 Diabetes and Associated Metabolic Disorders

John O Olukorode et al. Cureus. .

Abstract

Glucagon-like peptide-1 (GLP-1) agonists have emerged as a groundbreaking class of medications for managing type 2 diabetes and associated metabolic disorders. These agents not only improve glycemic control by increasing insulin secretion and reducing glucagon levels but also promote significant weight loss, enhance cardiovascular and renal health, and offer potential neuroprotective benefits. Their multifaceted mechanisms include appetite suppression, increased energy expenditure, and direct neuroprotective effects. GLP-1 agonists have shown recent benefits in Obstructive Sleep Apnea, and the treatment of neurodegenerative diseases such as Alzheimer's and Parkinson's, as well as reducing the risk of stroke. This review highlights the therapeutic potential of GLP-1 agonists in diabetes management and beyond, advocating for continued research to optimize their clinical use and explore new therapeutic avenues.

Keywords: benefits of glp-1 agonists; diabetes; glp-1 agonist; glucagon-like peptide; liraglutide; management of type 2 diabetes; obstructive sleep apnea; tirzepatide.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

    1. Biology of incretins: GLP-1 and GIP. Baggio LL, Drucker DJ. https://doi.org/10.1053/j.gastro.2007.03.054. Gastroenterology. 2007;132:2131–2157. - PubMed
    1. Pharmacology, physiology, and mechanisms of incretin hormone action. Campbell JE, Drucker DJ. https://doi.org/10.1016/j.cmet.2013.04.008. Cell Metab. 2013;17:819–837. - PubMed
    1. Cardiovascular effects of glucagonlike peptide-1 agonists. Davidson MH. http://10.1016/j.amjcard.2011.03.046 Am J Cardiol. 2011;108:33–41. - PubMed
    1. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Drucker DJ. https://doi.org/10.1016/j.cmet.2018.03.001. Cell Metab. 2018;27:740–756. - PubMed
    1. Exendin-4 from Heloderma suspectum venom: from discovery to its latest application as type II diabetes combatant. Yap MK, Misuan N. https://doi.org/10.1111/bcpt.13169. Basic Clin Pharmacol Toxicol. 2019;124:513–527. - PubMed

LinkOut - more resources